tiprankstipranks
Trending News
More News >
Gland Pharma Ltd. (IN:GLAND)
:GLAND
India Market

Gland Pharma Ltd. (GLAND) Stock Statistics & Valuation Metrics

Compare
0 Followers

Total Valuation

Gland Pharma Ltd. has a market cap or net worth of ₹308.73B. The enterprise value is ₹298.88B.
Market Cap₹308.73B
Enterprise Value₹298.88B

Share Statistics

Gland Pharma Ltd. has 164,756,420 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding164,756,420
Owned by Insiders
Owned by Institutions

Financial Efficiency

Gland Pharma Ltd.’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 11.55%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)11.55%
Return on Capital Employed (ROCE)0.18
Revenue Per Employee
Profits Per Employee
Employee Count
Asset Turnover0.50
Inventory Turnover1.36

Valuation Ratios

The current PE Ratio of Gland Pharma Ltd. is 36.64. Gland Pharma Ltd.’s PEG ratio is 1.61.
PE Ratio36.64
PS Ratio0.00
PB Ratio10.38
Price to Fair Value2.80
Price to FCF600.07
Price to Operating Cash Flow160.37
PEG Ratio1.61

Income Statement

In the last 12 months, Gland Pharma Ltd. had revenue of 56.17B and earned 6.99B in profits. Earnings per share was 42.40.
Revenue56.17B
Gross Profit33.27B
Operating Income17.33B
Pretax Income10.63B
Net Income6.99B
EBITDA12.69B
Earnings Per Share (EPS)42.40

Cash Flow

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00

Dividends & Yields

Gland Pharma Ltd. pays an annual dividend of ₹20, resulting in a dividend yield of 1.07%
Dividend Per Share₹20
Dividend Yield1.07%
Payout Ratio37.02%
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.41
52-Week Price Change0.44%
50-Day Moving Average1.59K
200-Day Moving Average1.65K
Relative Strength Index (RSI)77.81
Average Volume (3m)6.85K

Important Dates

Gland Pharma Ltd. upcoming earnings date is Jul 16, 2025, TBA (Confirmed).
Last Earnings DateMay 20, 2025
Next Earnings DateJul 16, 2025
Ex-Dividend DateAug 14, 2025

Financial Position

Gland Pharma Ltd. as a current ratio of 4.33, with Debt / Equity ratio of 0.23%
Current Ratio4.33
Quick Ratio3.26
Debt to Market Cap0.01
Net Debt to EBITDA-1.77
Interest Coverage Ratio41.27

Taxes

In the past 12 months, Gland Pharma Ltd. has paid 3.64B in taxes.
Income Tax3.64B
Effective Tax Rate0.34

Enterprise Valuation

Gland Pharma Ltd. EV to EBITDA ratio is 18.40, with an EV/FCF ratio of 44.04.
EV to Sales4.16
EV to EBITDA18.40
EV to Free Cash Flow44.04
EV to Operating Cash Flow25.53

Balance Sheet

Gland Pharma Ltd. has ₹30.50B in cash and marketable securities with ₹3.14B in debt, giving a net cash position of -₹27.36B billion.
Cash & Marketable Securities₹30.50B
Total Debt₹3.14B
Net Cash-₹27.36B
Net Cash Per Share-₹166.07
Tangible Book Value Per Share₹533.96

Margins

Gross margin is 57.00%, with operating margin of 30.86%, and net profit margin of 12.44%.
Gross Margin57.00%
Operating Margin30.86%
Pretax Margin18.92%
Net Profit Margin12.44%
EBITDA Margin22.59%
EBIT Margin15.86%

Analyst Forecast

The average price target for Gland Pharma Ltd. is ₹1,435.00, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target₹1,435.00
Price Target Upside-4.08% Downside
Analyst ConsensusModerate Sell
Analyst Count1
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart ScoreN/A
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis